{
  "input": {
    "mode": "revise",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "t_tnf_inhibition",
          "type": "Target",
          "label": "TNF Inhibition",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "t_il_17_pathway",
          "type": "Target",
          "label": "IL-17 Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "t_il_23_pathway",
          "type": "Target",
          "label": "IL-23 Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "p_psoriasis_pathway",
          "type": "Pathway",
          "label": "Psoriasis Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot1",
          "type": "Target",
          "label": "OffTargetInflammation",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp1",
          "type": "Pathway",
          "label": "RiskPathwayChronicInflammation",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv1",
          "type": "Phenotype",
          "label": "AdversechronicCondition",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Acitretin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Apremilast",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Brodalumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Etanercept",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Guselkumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Secukinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_acitretin",
          "target": "t_psoriasismediators",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "已知作用于皮肤组织"
        },
        {
          "source": "drug_adalimumab",
          "target": "t_tnf_inhibition",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "TNF 抑制直接相关"
        },
        {
          "source": "drug_apremilast",
          "target": "t_il_17_pathway",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "与 IL-17 途径调节关联"
        },
        {
          "source": "drug_brodalumab",
          "target": "t_il_17_pathway",
          "relation": "inhibits",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "针对 IL-17 的抑制作用"
        },
        {
          "source": "drug_etanercept",
          "target": "t_tnf_inhibition",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接抑制 TNF"
        },
        {
          "source": "drug_guselkumab",
          "target": "t_il_23_pathway",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-23 抑制机制关联"
        },
        {
          "source": "drug_infliximab",
          "target": "t_tnf_inhibition",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "TNF 抑制剂"
        },
        {
          "source": "drug_ixekizumab",
          "target": "t_il_17_pathway",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "通过 IL-17 的抑制作用"
        },
        {
          "source": "drug_methotrexate",
          "target": "p_psoriasis_pathway",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "与银屑病治疗常识一致"
        },
        {
          "source": "drug_secukinumab",
          "target": "t_il_17_pathway",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接抑制 IL-17"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "t_il_23_pathway",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-23 抑制有效性"
        },
        {
          "source": "drug_ustekinumab",
          "target": "t_il_23_pathway",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "针对 IL-23 的抑制机制"
        },
        {
          "source": "t_tnf_inhibition",
          "target": "p_psoriasis_pathway",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "通路参与关系"
        },
        {
          "source": "t_il_17_pathway",
          "target": "p_psoriasis_pathway",
          "relation": "involved_in",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "IL-17 在皮炎过程中的角色"
        },
        {
          "source": "t_il_23_pathway",
          "target": "p_psoriasis_pathway",
          "relation": "involved_in",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "皮肤相关路径参与"
        },
        {
          "source": "p_psoriasis_pathway",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "病理学上已知关联"
        },
        {
          "source": "drug_acitretin",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_adalimumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_apremilast",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_brodalumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_etanercept",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_guselkumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_infliximab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_ixekizumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_methotrexate",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_secukinumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_ustekinumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "n_acitretin",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_adalimumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_apremilast",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_brodalumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_etanercept",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_guselkumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_infliximab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ixekizumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_methotrexate",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_secukinumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_tildrakizumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ustekinumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ot1",
          "target": "n_rp1",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "与慢性炎症反应相关"
        },
        {
          "source": "n_rp1",
          "target": "n_adv1",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良慢性病理情况"
        },
        {
          "source": "n_adv1",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H6",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H7",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H8",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H9",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H10",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H11",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H12",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        }
      ],
      "round_index": 3
    },
    "history": {
      "round": 3,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.73,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Acitretin 直接支持适应症，并调节皮肤炎症途径"
            ],
            "safety_risk": [
              "潜在导致的不良慢性病理情况风险较高"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H2",
          "score": 0.7,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.8,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.9,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Adalimumab 直接抑制 TNF，不良反应与适应症吻合"
            ],
            "safety_risk": [
              "存在可能导致慢性炎症的风险"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H3",
          "score": 0.72,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Apremilast 的 IL-17 调节作用适合治疗"
            ],
            "safety_risk": [
              "潜在不良慢性情况的风险警告"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H4",
          "score": 0.74,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.8,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Brodalumab 有效抑制 IL-17"
            ],
            "safety_risk": [
              "与慢性病理条件相关的不良反应警告"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H5",
          "score": 0.68,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Etanercept 直接抑制 TNF，具有应用基础"
            ],
            "safety_risk": [
              "可能导致慢性病理状态"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H6",
          "score": 0.7,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Guselkumab 针对 IL-23 的抑制作用基于理论"
            ],
            "safety_risk": [
              "可能导致炎症靶点不良反应"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H7",
          "score": 0.71,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Infliximab 作为 TNF 抑制剂，相关性强"
            ],
            "safety_risk": [
              "与慢性炎症相关的风险报告"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H8",
          "score": 0.65,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.65,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Ixekizumab 的 IL-17 抑制有应用基础"
            ],
            "safety_risk": [
              "可能导致的炎症靶点影响"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H9",
          "score": 0.62,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.6,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Methotrexate 在银屑病的治疗应用较广，但机制不明"
            ],
            "safety_risk": [
              "存在较高的不良反应风险"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H10",
          "score": 0.75,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Secukinumab 有效抑制 IL-17，符合适应症"
            ],
            "safety_risk": [
              "不良反应相关性低"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H11",
          "score": 0.68,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Tildrakizumab 对 IL-23 的抑制为主机制"
            ],
            "safety_risk": [
              "存在的慢性炎症风险应关注"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H12",
          "score": 0.67,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.1,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.06
          },
          "graph_signals": {
            "support_weight": 0.65,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Ustekinumab 也有效针对 IL-23"
            ],
            "safety_risk": [
              "潜在的不良慢性病理影响需考虑"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65
    },
    "heuristic_priors": []
  },
  "output": {
    "revisions": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "慢性病理条件风险",
            "expectation": "若风险成立，标注高权重的 refutes 边",
            "assignee": "Skeptic"
          },
          {
            "type": "add_mechanism_link",
            "from": "drug_acitretin",
            "via": [
              "t_psoriasismediators"
            ],
            "to": "d_generalised_pustular_psoriasis",
            "success_criteria": "补充 Drug→Target→Disease 路径以巩固机制依赖性",
            "assignee": "Proponent"
          }
        ],
        "debate_focus": [
          "明确慢性病理条件与治疗净获益的相互影响",
          "Acitretin 的整体治疗适应症及其长期效果"
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "慢性病理条件风险",
            "expectation": "若风险成立，标注高权重的 refutes 边",
            "assignee": "Skeptic"
          },
          {
            "type": "add_mechanism_link",
            "from": "drug_adalimumab",
            "via": [
              "t_tnf_inhibition"
            ],
            "to": "d_generalised_pustular_psoriasis",
            "success_criteria": "补充 Drug→Target→Disease 路径以巩固机制依赖性",
            "assignee": "Proponent"
          }
        ],
        "debate_focus": [
          "明确慢性病理条件与治疗净获益的相互影响",
          "Adalimumab 的整体治疗适应症及其长期效果"
        ]
      }
    ],
    "pruned_hypotheses": [],
    "new_subhypotheses": [],
    "seed_request": {
      "should_regenerate": true,
      "reason": "多个假设均面临显著的慢性病理条件相关风险且缺乏机制连接性，需引入更具直接治疗适应症的药物候选。",
      "n": 4
    }
  }
}